[go: up one dir, main page]

AR045037A1 - Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. - Google Patents

Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.

Info

Publication number
AR045037A1
AR045037A1 ARP040102391A ARP040102391A AR045037A1 AR 045037 A1 AR045037 A1 AR 045037A1 AR P040102391 A ARP040102391 A AR P040102391A AR P040102391 A ARP040102391 A AR P040102391A AR 045037 A1 AR045037 A1 AR 045037A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
conh
heterocyclyl
Prior art date
Application number
ARP040102391A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0308442A external-priority patent/FR2857363B1/fr
Priority claimed from FR0308441A external-priority patent/FR2857362B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR045037A1 publication Critical patent/AR045037A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere principalmente a nuevas tetrahidro-1H-pirazolo[3,4-c]piridinas sustituidas que tienen una actividad terapéutica, utilizables en particular en oncología y composiciones que las contienen. Reivindicación 1: Producto de la fórmula general (1) siguiente, y sus tautómeros, caracterizado porque: L se elige entre enlace, -CH2, CO, SO2, CONH, COO, NHCO, NH, NHSO2, SO2NH, NHCONH, CH2NH y NHCH2; X se elige entre enlace, CH2, CO, SO2, CONH y COO; R1 se elige entre OH, H, alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, eventualmente sustituido y, cuando X es enlace, entonces R1 también puede ser halógeno; R2 es H o se elige entre alquilo, alquileno, cicloalquilo, heterociclilo, arilo y heteroarilo, eventualmente sustituido; y porque los sustituyentes se eligen independientemente entre R3, O-R3, halógeno, NO2, SO2-R3, CO-R3, SO2NH-R3, CONH-R3, N-(R3)2, NHCO-R3, NHSO2-R3, NHCONH-R3, NHSO2NH-R3, OCO-R3, COO-R3, OSO2-R3, SO2O-R3, OCONH-R3 y OSO2NH-R3, en el que cada R3 se elige independientemente entre H, alquilo, cicloalquilo, alquenilo, arilo, heteroarilo y heterociclilo, eventualmente sustituido con halógeno, arilo, heteroarilo, R4, OR4 y N(R4)2, en el que cada R4 se elige independientemente entre H, alquilo C1-4 y alquilo halogenado C1-4
ARP040102391A 2003-07-10 2004-07-07 Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. AR045037A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0308442A FR2857363B1 (fr) 2003-07-10 2003-07-10 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
FR0308441A FR2857362B1 (fr) 2003-07-10 2003-07-10 Tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
AR045037A1 true AR045037A1 (es) 2005-10-12

Family

ID=34081983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102391A AR045037A1 (es) 2003-07-10 2004-07-07 Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.

Country Status (12)

Country Link
US (2) US7109340B2 (es)
EP (2) EP1646632A2 (es)
JP (1) JP4740841B2 (es)
KR (1) KR20060054291A (es)
AR (1) AR045037A1 (es)
AU (1) AU2004256945B2 (es)
BR (1) BRPI0412411A (es)
CA (1) CA2532122A1 (es)
IL (1) IL172994A0 (es)
MX (1) MXPA06000247A (es)
TW (1) TW200519110A (es)
WO (1) WO2005007653A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
FR2888579A1 (fr) * 2005-07-13 2007-01-19 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
RU2404776C2 (ru) * 2005-01-28 2010-11-27 Новартис Аг ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2
ATE409190T1 (de) * 2005-04-14 2008-10-15 Hoffmann La Roche Tricyclische azolderivate, ihre herstellung und ihre verwendung als pharmazeutische mittel
JP2009530337A (ja) * 2006-03-23 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー 置換インダゾール誘導体、その製造方法、及びその薬剤としての利用法
WO2008060568A2 (en) * 2006-11-15 2008-05-22 Neurogen Corporation Amide-substituted aryl piperidines
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015168286A1 (en) * 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節n−アシル−トリアゾロピラジン
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CA3111309A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
MX2021003737A (es) * 2018-09-28 2021-05-14 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa.
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
BR112022013849A2 (pt) * 2020-01-13 2022-09-13 Aptabio Therapeutics Inc Novo derivado de pirazol
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77517A (hu) * 1994-10-20 1998-05-28 Pfizer Inc. Biciklusos tetrahidro-pirazolo-piridin-származékok, alkalmazásuk és ilyen vegyületeket tartalmazó gyógyászati készítmények
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ES2202827T3 (es) 1997-03-19 2004-04-01 ABBOTT GMBH & CO. KG Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999017770A1 (en) 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CA2314355A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE270549T1 (de) 1998-04-30 2004-07-15 Abbott Gmbh & Co Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
NZ510587A (en) 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
PL348210A1 (en) 1998-11-06 2002-05-06 Basf Ag Tricyclic pyrazole derivatives
MXPA01012442A (es) 1999-06-03 2004-09-10 Abbott Gmbh & Co Kg Compuestos de benzotiazinona y benzoxazinona.
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ES2228629T3 (es) 1999-11-22 2005-04-16 Smithkline Beecham Plc Derivados de imidazol y su uso como inhibidores de raf-quinasa.
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
EP1325006A2 (en) 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
MXPA03001169A (es) * 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
EP1372648B1 (en) 2001-01-19 2006-03-15 Smithkline Beecham Corporation Tie2 receptor kinase inhibitors for treating angiogenic diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076463A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076984A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002303145A1 (en) 2001-03-23 2002-10-08 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003004488A1 (en) 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
FR2827861B1 (fr) * 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
US7101884B2 (en) * 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
US7265128B2 (en) * 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu

Also Published As

Publication number Publication date
JP4740841B2 (ja) 2011-08-03
CA2532122A1 (fr) 2005-01-27
US7109340B2 (en) 2006-09-19
WO2005007653A2 (fr) 2005-01-27
JP2007516186A (ja) 2007-06-21
KR20060054291A (ko) 2006-05-22
IL172994A0 (en) 2006-06-11
US20060199837A1 (en) 2006-09-07
BRPI0412411A (pt) 2006-08-22
AU2004256945A1 (en) 2005-01-27
US20050096345A1 (en) 2005-05-05
TW200519110A (en) 2005-06-16
US7435820B2 (en) 2008-10-14
MXPA06000247A (es) 2006-03-30
EP2251340A1 (fr) 2010-11-17
AU2004256945B2 (en) 2009-08-20
EP1646632A2 (fr) 2006-04-19
WO2005007653A3 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
AR045037A1 (es) Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DK1288205T3 (da) Nye phenylalanin-derivater
NO20034644D0 (no) Fettsyrer med halvlange kjeder, glycerider og analoger som neutrofile overlevelses- og aktiveringsfaktorer
BR0214277A (pt) Solvatos de paclitaxel
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
DE60033684D1 (de) Phenylalaninderivate
AR012020A1 (es) COMPUESTOS DE N - (TRIAZOLOAZINIL)ARILSULFONAMIDAS, COMPOSICIONES HERBICIDAS QUE LOS COMPRENDEN, MÉTODO PARA CONTROLAR VEGETACIoN INDESEABLE MEDIANTE SU APLICACIoN Y COMPUESTOS INTERMEDIARIOS uTILES COMO INTERMEDIARIOS EN SU PREPARACIoN.
PE20040522A1 (es) Derivados de diarilurea dependientes de la cinasa de proteina
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
UY26957A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
EP2615087A3 (en) Phenylalanine derivatives
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DE69006482D1 (de) Anti-krebs-verbindungen.
DE69701298D1 (de) Hydroxypyridin-Derivate, ihre Herstellung und ihre pharmazeutische Verwendung
AR035196A1 (es) Derivados de guanidina o biguanidina y el uso de los mismos para la fabricacion de medicamentos antivirales y antimicrobianos
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
CO6150166A2 (es) Nuevos derivados de [1,3]tiazolo[4,5-d]pirimidin-2-(3h)-amina 5,7-disustituidos y su uso en terapia
CO4180512A1 (es) Sulfonamidas en base peptidilo, utiles para el tratamiento del sida
AR031837A1 (es) Derivados amino substituidos ramificados de 3-amino-1-fenil-1h [1, 2, 4] triazol, su utilizacion, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
IS4725A (is) Afleiður amidíns og ísóþíóþvagefnis er hindra nítrítoxíðsyntasa
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ITMI921559A1 (it) Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
DE602004007181D1 (de) 2,4,6-tris(4'aminobenzaldineopentylmalonat)-s-triazin, dieser enthaltenden Sonnenschutzzusammensetzungen und dessen Verwendungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure